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Abstract: For the clinical development of a new drug, the determination of dose-proportionality is an essential 18 
part of the pharmacokinetic evaluations. Including goodness-of-fit evaluations of the applied statistical models in 19 
dose-proportionality considerations may be able to provide early indications of non-linear pharmacokinetics and 20 
identify sub-populations with divergent clearances. We propose the use of simulation based visual predictive 21 
checks as goodness-of-fit examinations to improve the validity of dose-proportionality conclusions for complex 22 
designs. We provide an illustrative example and include a table to facilitate review by regulatory authorities. 23 
1. Introduction 24 
In early clinical development, the disposition of new drugs determines the feasibility of its further development. 25 
The assessment of dose-proportionality is of great clinical importance for predicting the consequences of rational 26 
dose adjustments [1]. It is of importance to identify a lack of proportionality since a moderate change in the 27 
bioavailability (BA) could have a large impact on the efficacy and safety for narrow therapeutic index drugs. 28 
Depending on the dosing range of the drug, non-proportional properties could challenge the use of the drug in 29 
clinical practice and may lead to the need of more extensive studies, for example in the context of bioequivalence.  30 
Essentially, a dose-proportionality assessment is performed to evaluate whether exposure increases proportionally 31 
with the dose. One can reasonably predict drug concentration for different dosing scenarios if the pharmacokinetics 32 
(PK) can be demonstrated to be dose-proportional. One of the key questions to be answered in a dose-33 
proportionality assessment is whether clearance is constant across the intended range of doses, which allows 34 
computation of an appropriate dose amount (i.e. dose per dosing interval) and dosing interval required to maintain 35 
an average steady-state plasma concentration which provides therapeutic benefit. Another critical element of a 36 
dose-proportionality assessment is that the data from all subjects are assumed to represent a homogenous 37 
population.  38 
The aim of the manuscript is to provide an overview of prior research on evaluation of dose-proportionality, add 39 
useful descriptions and definitions of these methodologies and illustrate how they are applied in practice. We 40 
further discuss a tool, the visual predictive check, which is often used for other pharmacokinetic applications, but 41 
which seems to have not been used for proportionality assessment, and which hasn’t received much attention in 42 
the statistical literature. 43 
Several analysis methods have been proposed to assess dose-proportionality. Examples are analysis of variance of 44 
dose-normalized PK metrics (see section 2 below), simple linear regression or a power model approach [2-5]. The 45 
power model is usually the preferred model of choice and used as a basis for decision making [4, 6]. The decision 46 
may be made by simply estimating the degree of non-proportionality or via an equivalence testing approach. Both 47 
approaches have been subject to research [e.g., 2 and 3], although mainly in the context of a parallel group design. 48 
In clinical practice, however, there is a lack of consensus on overarching standardized rules for the analysis and 49 
reporting of dose-proportionality assessments. 50 
The concepts of linear pharmacokinetics, dose-proportionality and dose-linearity are closely related. To put these 51 
into context, we first explain the term linear pharmacokinetics and subsequently examine the concept of and 52 
consequences of dose-proportionality, before a brief description of dose-linearity. The remainder of the paper is 53 
dedicated to establishing a generic framework for the assessment of dose-proportionality. This comprises parallel 54 
group designs, but also more complex trial designs such as cross-over or alternate panel designs. We provide 55 
recommendations for the analysis and the assessment of goodness-of-fit and for reporting of results from such an 56 
investigation. Finally, we illustrate the proposed framework with a practical study example and provide the 57 
corresponding code for the statistical software R [7]. 58 
2. Terminology 59 
Pharmacokinetic characteristics in early stages of drug development are typically quantified and described using 60 
a non-compartmental (NCA) approach. The corresponding estimated quantities (e.g., Cmax, AUC0–t, etc) are 61 
referred to as PK metrics instead of PK parameters since the latter are elements of a PK model which are not 62 
directly observable, and which describes concentration as a function of time and other factors.  63 
Linear pharmacokinetics theoretically requires that all transport processes (e.g. absorption, distribution, 64 
elimination) can be described by first order kinetics, in which the instantaneous rate of change of concentration 65 
depends only on the current concentration (i.e., the rate of change for concentration is proportional to the current 66 
concentration). Therefore, transport processes which are not described by first order kinetics will lead, in general, 67 
to non-linear pharmacokinetics.  68 
On the premise of linear pharmacokinetics: 69 
• Changing dose by the factor k leads to the corresponding change of any individual concentration by the 70 
same factor k at any given time point. This means that PK metrics which are simple linear functions of 71 
concentration, such as area under the curve (AUC), maximum concentration (Cmax), and trough 72 
concentration (Ctrough) change proportionally with dose  73 
• PK metrics such as time to reach maximum concentration (tmax), apparent terminal half-life (t½), systemic 74 
clearance (CL), volume of distribution at steady state (Vss), mean residence time (MRT), and 75 
bioavailability (F) are independent of dose, as may be surmised by examination of the units of 76 
measurement 77 
• Concentrations after repeated dosing can be predicted, by the principle of superposition, from 78 
concentrations following a single dose (e.g., AUC0–τ at steady state equals AUC0–∞ after a single dose 79 
where τ represents the constant dosing interval). 80 
The premise of linear pharmacokinetics may be shown to be unsupportable when exposure is not proportional to 81 
dose. However, demonstrating dose-proportionality alone does not prove linear pharmacokinetics. For example, 82 
there might be situations with linear clearance (i.e. concentration independent) although plasma or tissue binding, 83 
or distribution may be non-linear. In addition, dose-proportionality or dose-linearity assessments are exposure 84 
analyses that are based on three or more dose levels using exposure metrics obtained with a non-compartmental 85 
approach (NCA) utilizing empirical models. These kinds of analyses are based on empirical observations rather 86 
than on theoretical pharmacokinetic properties and cannot provide details on the different PK processes which 87 
might impact dose-proportionality or dose-linearity. 88 
3. Concept of dose-proportionality 89 
Dose-proportionality over a dose range after a single administration can be assessed empirically by the power 90 
model [2-4] which has the following form: 91 
𝑌𝑌 = 𝜇𝜇 × 𝑑𝑑𝛽𝛽 (1) 92 
where Y represents the exposure metric of interest (e.g., maximum concentration Cmax, area under the curve from 93 
zero to the last time point with a quantifiable concentration AUC0-tlast, area under the curve from zero to infinity 94 
AUC0–∞) and d the corresponding dose administered. On the premise of dose-proportionality, the parameter of 95 
interest β equals 1 (i.e., the relationship between dose and exposure is given as a straight line passing through zero 96 
on the ordinate). Lack of dose-proportionality can be due to many mechanisms (e.g. limited solubility will result 97 
in a less than proportional increase) but is typically due to the saturation of some components in the system (e.g. 98 
under proportionality for saturable absorption and over proportionality for a saturable metabolism process [8]). A 99 
comprehensive discussion regarding mechanisms leading to lack of dose-proportionality is provided in [9] and 100 
will therefore not be further discussed. 101 
Note that when we discuss proportionality it is necessary to specify a range over which proportionality will be 102 
assessed. This is because proportionality from zero to infinity is not physically plausible, and for practical 103 
applications we just need a defined range of proportionality. Assessing dose-proportionality over a dose range can 104 
be considered as an equivalence hypothesis problem and can be assessed utilizing the power model based on 105 
certain margins of equivalence [2,3]. In this setting, the corresponding acceptance regions for the parameter β from 106 
the power model can be derived based on conventional margins of (bio)equivalence ranging from θL = 0.8 to 107 
θU = 1.25 [2] or based on a more lenient acceptance criterion ranging from θL = 0.5 to θU=2.0 arguing that the 108 
conventional margins are impractically strict for large dose ranges [3]. Acceptance regions can be derived as 109 
follows [2,3]: 110 
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where r corresponds to the dose ratio investigated relating acceptance regions to the dose range. It follows that the 112 
acceptance region is more stringent for a large dose range than for a narrow dose range. If the calculated two-sided 113 
90% confidence interval for the estimated slope β falls completely within the acceptance region, dose-114 
proportionality over a dose range can be claimed statistically at the 5% level of significance [10] which allows a 115 
yes/no decision in the case that margins were specified a-priori. If the calculated two-sided 90% confidence interval 116 
(CI) for the estimated slope β doesn’t completely fall within the acceptance region, the highest dose maxD̂  can be 117 
calculated such that the two-sided 95% CI for β is included entirely within the pre-specified margin [2] by: 118 
𝐷𝐷�𝑚𝑚𝑚𝑚𝑚𝑚 = 𝐷𝐷𝑚𝑚𝑚𝑚𝑙𝑙 × 𝜃𝜃𝑈𝑈
1
𝑚𝑚𝑚𝑚𝑚𝑚(1−𝐿𝐿,𝑈𝑈−1) (3) 119 
where Dmin is the lowest dose studied and L and U the lower and upper limits of the two-sided 90% confidence 120 
interval for slope β, respectively. Extrapolation beyond the studied dose range is typically not recommended. 121 
A definitive assessment of confirmatory dose-proportionality is generally conducted during later phases. The 122 
corresponding sample size planning is discussed in [11] and can be performed by function power.dp of R 123 
package PowerTOST [12].  124 
For the possibility of considering a waiver for investigation of additional dose amounts in the context of 125 
bioequivalence studies, the corresponding EMA guideline [13] suggests an equivalence margin for dose-126 
normalized AUCs of ±25% which would allow evaluating bioequivalence at the highest dose only where for other 127 
doses a waiver is possible via a dissolution similarity exercise. Of note, the power model has a direct relationship 128 
to dose-normalized AUCs because on the premise of dose-proportionality the equation Y/d=a=constant holds true. 129 
Consequently using ±25% as margin for dose-normalized AUCs leads therefore to margins of θL = 0.75 to 130 
θU = 1/0.75 for the estimated slope β. It should be noted that analysis of dose-normalized exposure metrics using 131 
analysis of variance (ANOVA) may be considered an inefficient use of available data since this approach handles 132 
the dose information as a categorical variable and therefore  may have less statistical power compared to the power 133 
model which explicitly utilizes dose information as a continuous variable [4]. 134 
It is commonly assumed that Cmax, AUC0–tlast, AUC0–∞ are log-normally distributed [14] with a proportional 135 
increase of the variance with the size of the PK metric (i.e., constant coefficient of variation rather than constant 136 
variance). For the situation at hand (i.e., assumed log-normally distributed exposure metrics with a proportional 137 
error), the transform-both-sides approach [15] using the natural logarithm results in the following functional 138 
relationship between dose and exposure: 139 
𝑙𝑙𝑙𝑙(𝑌𝑌) = 𝑙𝑙𝑙𝑙(𝜇𝜇) + 𝛽𝛽 × 𝑙𝑙𝑙𝑙(𝑑𝑑) + ε (4) 140 
where ε represents a normally distributed residual error with zero mean and a common variance. 141 
Dose-proportionality over a dose range after repeated administration at steady state can also be assessed based on 142 
PK metrics Cmax;ss, Ctrough;ss and AUC0–τ;ss grounded on this concept. However, it should be noted that evaluation 143 
of Ctrough;ss can be difficult in case of values below the lower limit of quantification (LLOQ) Also, AUC0–∞ is 144 
typically not calculated at steady state since it would not be interpretable whenever accumulation occurs, and 145 
therefore one would need to carefully consider and justify the use of this metric for evaluation of dose 146 
proportionality after repeated administration. 147 
As already mentioned, one of the key questions to be answered in a dose-proportionality assessment is whether 148 
clearance is constant across the selected dose range. Apparent clearance is calculated as dose/AUC, so that AUC 149 
can be used to examine whether apparent clearance appears to be a constant across the dose range. However, there 150 
can be situations where AUCs may appear to be dose proportional but individual concentration time curves are 151 
not. This is the motivation for evaluating dose-proportionality also on other exposure metrics such as Cmax or 152 
Ctrough. Cmax is important regarding the potential for safety concerns which may arise if one might experience of 153 
unexpectedly high peak exposure. Likewise, Ctrough may be a critical consideration for efficacy, such as FVIII for 154 
hemophilia patients, where maintenance of a suitably high Ctrough is important.  155 
Lastly, as alluded to above, most compounds can be expected to exhibit a non-linear relationship between dose 156 
and exposure when administered over a sufficiently large range (i.e., at extreme doses). Therefore, one should only 157 
assess dose-proportionality for the clinically relevant or defined dose range, although a broader dose range is 158 
typically investigated in early pharmacological studies since a final recommended dose range is not yet known or 159 
decided upon. Another point to consider is that drugs may be evaluated at a large dose range during clinical 160 
development, but much smaller dose ranges may apply in various situations, such as for different indications. For 161 
instance, intravenous immunoglobulins are used at doses between 0.4 to 2 g/kg body mass [16], but narrower dose 162 
ranges are used for replacement therapy (0.4–0.8 g/kg) and immunomodulating therapies (1–2 g/kg). More 163 
generally the recommended dose range may vary for different countries, by age, by body weight, by hepatic or 164 
renal impairment, for concomitant medications, or by other factors which may impact the dose-exposure 165 
relationship. 166 
In contrast to dose-proportionality, dose-linearity after a single dose study implies that the relationship between 167 
dose and exposure (e.g., AUC) is given as a straight line starting on the ordinate at any value greater or smaller 168 
than zero. This concept is therefore applicable for a) endogenous compounds implying starting on the ordinate at 169 
a value greater than zero or b) compounds that are invariably lost upon administration at low dose levels (e.g., a 170 
low dose of a drug which is given far in excess of a receptor) starting on the ordinate on a value lower than zero. 171 
Consequently, an alternate non-linear modeling approach, such as model 4 in [17], may need to be considered as 172 
a basis for a description of the underlying relationship between dose and exposure.  173 
4. Assessing Goodness-of-fit 174 
Prior to making any conclusions regarding dose-proportionality, the goodness-of-fit of the model must be assessed 175 
to evaluate the model performance which is usually done using graphical evaluation. These assessments should 176 
include residual diagnostic plots (i.e., plotting residuals versus predicted). A comprehensive model evaluation 177 
should also include plotting the residuals (y-axis) against potential covariates (x-axis) which may represent a sub-178 
population with different drug clearance profiles (e.g. race, ethnicity, sex, age, disease status, phenotypes, etc). If 179 
these figures show any unacceptable trends (i.e. not symmetrically scattered residuals around zero), inclusion of 180 
covariates in the model or sub-group analyses should be considered.  181 
An important goodness-of-fit plot is a scatter plot of the observed dose-exposure values superimposed with the 182 
model-predicted dose-exposure relationship, along with corresponding confidence and prediction intervals [2] on 183 
linear-linear and log-log scales. However, the latter goodness-of-fit plot brings along some difficulties when more 184 
complex designs are used. This section provides a solution to the difficulties that goodness-of-fit plots exhibit for 185 
more complex designs. 186 
As mentioned above, the power model can be straightforwardly applied to exposure metrics estimated from a 187 
parallel group design using the following simple linear regression model: 188 
𝑙𝑙𝑙𝑙(𝑌𝑌𝑚𝑚) = 𝑙𝑙𝑙𝑙( 𝜇𝜇) + 𝛽𝛽 × 𝑙𝑙𝑙𝑙(𝑑𝑑𝑚𝑚) + 𝜀𝜀𝑚𝑚 (7) 189 
where Yi represents the exposure metric of interest and di the corresponding dose for subject i. Model parameter µ 190 
represents the intercept, i.e. the average ln(Y) value for ln(d) = 0, and β the slope, i.e. the increase of ln(Y) for an 191 
increase of 1 unit in ln(d). The residual error ε is a normally distributed random variable with mean zero and 192 
common variance. A plot of the observed dose-exposure values superimposed with the model predicted dose-193 
exposure relationship, along with corresponding confidence and prediction intervals, can be derived easily. 194 
However, dose-proportionality is frequently assessed using a more complex design, such as higher order cross-195 
over designs, which in turn requires the application of more complex models, with additional parameters taking 196 
the design features into account. We generally recommend a balanced design which requires that 1) each dose 197 
occurs only once with each subject, 2) each dose occurs the same number of times in each period and 3) the number 198 
of subjects who receive dose i in some period followed by dose j in the next period is the same for all i ≠ j. 199 
Alternate panel designs (e.g., single sequence k period design) do not meet the properties of a balanced design and 200 
require additional unverifiable premises such as of no period effect and is typically evaluated using a linear mixed 201 
effects model with log-transformed dose as a fixed effect and subject as a random effect. However, Williams’ 202 
designs (i.e., special cases of orthogonal Latin squares design) meet these properties of a balanced design and the 203 
following equation shows how to model the dose-exposure relationship for a higher order cross-over design [18]: 204 
𝑙𝑙𝑙𝑙(𝑌𝑌𝑚𝑚𝑖𝑖𝑖𝑖) = 𝑙𝑙𝑙𝑙(𝜇𝜇) + 𝛽𝛽 × 𝑙𝑙𝑙𝑙(𝑑𝑑𝑚𝑚𝑖𝑖𝑖𝑖) + 𝑝𝑝𝑖𝑖 + 𝑠𝑠𝑖𝑖 + 𝛾𝛾𝑚𝑚𝑖𝑖 + 𝜀𝜀𝑚𝑚𝑖𝑖𝑖𝑖 (8) 205 
where µ represents the intercept parameterized as the average ln(Y) value for ln(d) = 0. Model parameter pj 206 
represents the fixed effect for period j and sk the fixed effect for sequence k. The effect for subject nested in 207 
sequence γ for subject i in sequence k can be modeled as fixed effect or as random (intercept) effect representing 208 
a normally distributed random variable with mean zero and common variance. Of note, the model in (8) fits a 209 
common slope to all subjects where the model can be easily expanded by modeling a normally distributed random 210 
slope 𝜃𝜃𝑖𝑖𝑖𝑖 with mean zero and common variance to get individual slopes for each subject.  211 
The estimated dose-exposure relationship now depends on additional fixed effects for period and sequence (and 212 
subject) preventing an overall assessment of goodness-of-fit by plotting observed dose-exposure values 213 
superimposed with the estimated dose-exposure relationship and corresponding confidence and prediction 214 
intervals.  215 
One possibility to overcome this issue is to use simulation based visual predictive checks (VPCs) to assess 216 
goodness-of-fit of the model. The general concept of VPCs is to assess graphically whether simulations from a 217 
model can reproduce the central trend as well as the variability in the observed data where Duffull et al. [19] may 218 
be the earliest recognizable use of VPCs with their figures 4 and 5. In a first step, many replicates of the original 219 
dataset are simulated from the model. Percentiles of interest for each simulated dataset are calculated and used to 220 
generate non-parametric confidence intervals for the predicted percentiles which are then superimposed with the 221 
observed percentiles. 222 
In situations with pronounced period and/or sequence effects, it may be helpful to perform this graphical 223 
assessment based on a period and sequence-corrected exposure metric Ycor and corresponding simulations to get a 224 
better understanding of the underlying inter-subject variability: 225 
𝑌𝑌𝑚𝑚𝑖𝑖𝑖𝑖𝑐𝑐𝑐𝑐𝑟𝑟 = 𝑒𝑒𝑒𝑒𝑝𝑝�𝑙𝑙𝑙𝑙(𝑌𝑌𝑚𝑚𝑖𝑖𝑖𝑖) − 𝑝𝑝𝑖𝑖 − 𝑠𝑠𝑖𝑖� (9) 226 
Typically, such studies are based on fixed dose groups and, therefore, observed and simulated percentiles can be 227 
straightforwardly calculated per dose group. If fixed doses are administered but body mass adjusted doses are of 228 
interest, it is possible that dose groups overlap after adjustment, and data needs to be grouped together by binning. 229 
If predictions within a bin differ largely due to different values of other independent variables, prediction corrected 230 
VPCs (pcVPC) should be employed [20]. Of note, VPCs are often used for complex models, such as population 231 
pharmacokinetic-pharmacodynamic (Pop PK/PD) modelling. We apply the model to a simpler log-transformed 232 
power model to illustrate its use in dose-proportionality assessments in the next section. 233 
5. Illustrative Example 234 
The following illustrative example was taken from Patterson and Jones [18]: A randomized cross-over study in 28 235 
normal healthy volunteers was performed to assess dose-proportionality (and the effect of food) using a Williams’ 236 
design (4 treatments, 4 sequences, 4 periods). Fixed doses of 1, 2, and 8 mg were administered after an overnight 237 
fast, with administration of each dose separated by a washout period. The fourth treatment was a fixed dose of 8 238 
mg with a meal instead of the overnight fast. Data of the latter regimen was not used for the assessment of dose-239 
proportionality. 240 
A linear mixed effects model using R function lmer of R package lme4 [21, 22] was fitted with fixed effects for 241 
period and sequence and a random (intercept) effect for subject nested in sequence. Corresponding VPCs for AUC 242 
on linear-linear and log-log scale based on 1,000 simulated data sets are shown in Figure 1. The corresponding R 243 
code for different goodness-of-fit plots is given as online supplement. 244 
Figure 1 shows no unacceptable trends since observed percentiles of interest were well within simulated non-245 
parametric 95% confidence intervals. Using the critical margins of 0.8 and 1.25 [2], dose-proportionality for the 246 
dose range investigated (1 to 8 mg) is judged to be satisfactory at the 5% level of statistical significance since the 247 
calculated two-sided 90% confidence interval for the estimated slope β falls completely within the critical region 248 
(Table 1). 249 
An additional alternate numerical model evaluation could be based on the power-model predicted geometric means 250 
per dose level as well as observed geometric means and their corresponding ratios. 251 
An illustrative example with an unacceptable trend based on simulated data is shown in Figure 2. The power model 252 
fails to reproduce the central trend of the data. The corresponding VPC shows the discrepancy of the model-based 253 
non-parametric confidence intervals with the percentiles of the observed data for the highest dose investigated 254 
indicating an approximately 20% smaller AUC than predicted by the model.  255 
 256 
 
Figure 1: Goodness of fit 
plots based on data from 
Patterson and Jones [18]. 
VPC for the power model on 
linear-linear (left panel) and 
log-log (right panel) scale 
based on 1,000 simulated 
data sets. The black lines are 
the 5th (dashed), 50th (solid) 
and 95th (dashed) percentiles 
based on the observed data. 
The shaded areas are non-
parametric 95% confidence 
intervals of the 5th (blue), 
50th (red) and 95th (blue) 
percentiles based on 
simulated data. The observed 
data are indicated by open 
circles. 
 
Figure 2: Goodness of fit 
plots based on data from a 
hypothetical example with an 
unacceptable trend. VPC for 
the power model on linear-
linear (left panel) and log-log 
(right panel) scale based on 
1,000 simulated data sets. 
The black lines are the 5th 
(dashed), 50th (solid) and 
95th (dashed) percentiles 
based on the observed data. 
The shaded areas are non-
parametric 95% confidence 
intervals of the 5th (blue), 
50th (red) and 95th (blue) 
percentiles based on 
simulated data. The observed 
data are indicated by open 
circles.  
 257 
6. Reporting of Results 258 
In the event that the goodness-of-fit plots shows unacceptable trends, any conclusions based on the power model 259 
are questionable and alternative models to describe the dose-exposure relationship can be utilized. In such cases 260 
we suggest investigating covariates to be included in the power model where influential covariates and their 261 
relationship to the exposure metric can be identified based on residual plots showing the relationship between 262 
residuals (y-axis) and covariates (x-axis). 263 
However, in case that the fitted basic power model does not show unacceptable trends and to facilitate 264 
interpretation of the dose-proportionality assessment in terms of clinical relevance, we recommend estimating the 265 
increase in the exposure metric per doubling of the dose [4]: 266 
Increase per doubling of dose = 𝑒𝑒𝑒𝑒𝑝𝑝(𝑙𝑙𝑙𝑙( 2) × 𝛽𝛽) (10) 267 
In addition to the factor for increase in PK metric, the size of deviation from dose-proportionality can be readily 268 
calculated from the power model and using the dose ratio (r) via [2,9]: 269 
Deviation from dose-proportionality =  𝑟𝑟𝛽𝛽−1 (11) 270 
As already mentioned, many compounds are expected to exhibit a non-linear relationship between dose and 271 
exposure when administered at extreme doses, which encourages a formal assessment of dose-proportionality for 272 
the a-priori specified anticipated clinical dose range in addition to the complete dose range investigated. We found 273 
a table like those presented in [2] useful for reporting the corresponding results.  274 
For the purpose of an exploratory assessment of dose-proportionality, acceptance regions for the slope based on 275 
[2] and/or [3] and/or [13] could be added as an additional column or footnote to the table to facilitate review by 276 
regulatory authorities. Table I shows results for the illustrative example where the deviation from dose-277 
proportionality is 4% (calculated as described in equation (11) as 81.02-1 = 1.04) regarding extent of absorption (i.e. 278 
the AUC is about 4% higher at an 8-fold increased dose than expected under dose-proportionality). 279 
Table I: Exploratory assessment of dose-proportionality based on the power model 
Dose range 
studied PK metric
* Model predicted geometric mean values* for dose range studied 
Estimated slope 
(90% CI) 
Increase in PK metric per 
doubling of dose 
(90% CI) 
1 to 8 (mg) 
AUC 346 – 2,901 1.02 (1.00 – 1.04) 
2.03 
(2.00 – 2.06) 
Cmax 75 – 588 
0.988 
(0.958 – 1.02) 
1.98 
(1.94 – 2.03) 
Acceptance region for the estimated slope as described in equation 2 according to Smith et al. [2]: 0.893 to 1.107 (±20%); EMA guideline 
[13]: 0.862 to 1.138 (±25%); Hummel et al. [3]: 0.667 to 1.333 (±50%). * Units of AUC and Cmax not available for the example in Patterson 
and Jones [18] 
7. Discussion and Conclusion 280 
Assessment of dose-proportionality over a dose range is an essential part of characterizing the PK properties of a 281 
drug during the development process. The dose-proportionality assessment is typically an exposure analysis of 282 
three or more dose levels based on exposure metrics obtained with the non-compartmental approach (NCA) 283 
utilizing an empirical model such as the power model. For this reason, a dose-proportionality assessment is based 284 
on empirical observations rather than on theoretical pharmacokinetic properties of the molecule at hand. 285 
Essentially, this kind of exposure analysis is aimed to evaluate whether exposure increases proportionally with 286 
dose where one of the key questions to be answered in a dose-proportionately assessment is whether clearance is 287 
“apparently” constant across an appropriate dose range. Dose-proportionality assessment can therefore be seen as 288 
a basic tool to help decide whether and which more advanced investigations are called for. This could be to use 289 
more sophisticated modeling approaches to better understand and characterize the compound or to collect 290 
additional data. 291 
In addition, different equivalence margins have been proposed which may limit the ability to satisfy different 292 
regulatory agencies of the appropriateness of the chosen values to support an “apparently” constant clearance 293 
across the recommended dose range; a globally acting sponsor company could easily end up with different 294 
decisions depending on the jurisdiction. The resulting uncertainty clearly has major potential implications on the 295 
internal decision- making process and induces unnecessary uncertainty in the “appropriate” margin. For this 296 
reason, choosing the strictest margins should therefore be considered in a confirmatory framework.  297 
However, we believe that, particularly in early drug development phases when the range of clinically relevant 298 
doses is not yet completely clear, the goodness-of-fit plots as well as the confidence intervals are more informative 299 
and important than the comparison to pre-specified margins of equivalence. This is because they provide 300 
information on 1) the adequacy of the model which serves as the basis for any further considerations, 2) the impact 301 
of the uncertainty of the estimates and 3) the possible size of exposure deviation from dose-proportionality for the 302 
dose range studied.  303 
An adequately powered and carefully conducted dose-proportionality assessment, including model evaluation 304 
based on goodness-of-fit plots, might be able to provide insights into possible non-linear pharmacokinetics and/or 305 
sub-populations with divergent clearances. This is difficult to achieve in complex designs and this article proposes 306 
simulation based VPCs to address this unmet need. 307 
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